• Q1 financial performance: Revenue rose 16% and EBITDA grew 18% with margins improving to 24.5%, supported by domestic formulation revenue growth of nearly 15% and volume growth of 8.4%.
• API segment recovery: The API business grew over 35% as operations fully normalized following last year's fire disruption, with a new CEO appointed to drive continued expansion.
• International formulation pipeline: Segment revenue grew 8% as the company secured OTC Naproxen approval in Canada, expanded into multiple African markets, and advanced five UK-based CDMO projects.
• Immunosuppressant growth target: The portfolio currently stands at ₹140 crore with 11% to 12% growth, with plans to surpass ₹200 crore via global expansion and in-house development of Tacrolimus.
• Cost inflation mitigation: Geopolitical uncertainties have caused no material business disruption, aided by existing inventory buffers, favorable foreign exchange movements, and price pass-through agreements with 13 global customers.